Skip to main content
. 2020 Oct 20;48(5):2185–2194. doi: 10.1042/BST20200424

Figure 2. Potential strategies for allosteric inhibition of LRRK2.

Figure 2.

Peptidomimetics can be used to disrupt LRRK2 dimerization (RocCOR : RocCOR, WD40 : WD40, WD40 : CORB,) and to interfere with LRRK2 PPIs (ARM domain: FADD). GTP-binding inhibition (FX2149) rescues LRRK2-mediated cellular toxicity. Peptide capping can prevent dephosphorylation of constitutively phosphorylated residues needed for interaction with 14.3.3. Nanobodies can be used to target and stabilize a low-kinase active conformation of LRRK2.